A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia

Chai-Coetzer, Ching Li (Chief Investigator (Project Lead))
Vakulin, Andrew (Chief Investigator)
Teare, Alison (Associate Investigator)
Mukherjee, Sutapa (Associate Investigator)
Adams, Robert (Associate Investigator)

Acronym	Vibrance-3
Status	Active
Effective start/end date	21/08/25 → 31/12/26